SlideShare a Scribd company logo
1
EuFMD | Open Session special edition | #OS20se
Comparison of Diagnostic Performances of Three Commercial ELISA Kits
for Detection of Antibodies to Foot-and-Mouth Disease Virus Type-O
Doheon Kwon, YouJin Han, JiHyun Lee, Hyun Mi Pyo, Eun-Jin Choi, Wonseok Shin, JaeMyoung Kim and Mi-Young Park
Foot and Mouth Disease Diagnostic Division, Animal and Plant Quarantine Agency, 177, Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do, Republic of Korea
INTRODUCTION
Vaccination has been the main strategy to prevent and control Foot-and-mouth Disease
(FMD) in Korea since 2010 and three FMD vaccines containing various strains has been
routinely used under national vaccination program since 2019. Furthermore, three
commercial ELISA kits have been licensed for detection of antibodies against structural
proteins (SP) of FMDV (Foot-and-mouth Disease Virus) to estimate vaccine-induced
immunity. These include PrioCHECK SP Type-O ELISA, accredited internationally and
two domestic solid-phase ELISA kits coated with recombinant protein-based antigens,
the latter two of which were approved in 2020. Since these various factors were
involved, variability in serological test results owing to differences in the antigenic
specificity of tests according to the particular virus strains and antibody reagents
utilized in the tests may affect the reliability of serological results. Therefore, we
investigated diagnostic performances of three ELISAs used for sero-surveillance to
monitor vaccine coverage and assess herd immunity in cattle and pigs.
MATERIALS & METHODS
A total of three FMDV SP type O ELISA kits licensed in Korea (Table 1) were evaluated
using 1540 sera collected from pigs and cattle vaccinated with one of three FMD
vaccines as described below (Table 2). In addition, 153 sera from unvaccinated pigs
experimentally infected with FMDV O/SKR/BE/2017 or O/SKR/AS/2019 and 368
negative sera from unvaccinated and uninfected animals were tested too. Also,
neutralizing antibody (NA) titers were determined with virus neutralization tests (VNT)
against homologous virus strains.
RESULTS
Country Supplier Serotype Antigens PD50
a
UK
Merial Animal
Health Ltd.
O+A
O Manisa, O 3039,
A22 Iraq
≥3PD50
Russia FGBI ARRIAH O+A
O Primorsky,
A Zabaikalsky
≥6PD50
Argentina Biogenesis Bago S.A O+A
O1 Campos, A24 Cruzeiro,
A2001 Argentina ≥6PD50
Table 2. Summary of FMD vaccines approved for routine use in Korea
Table 1. Characteristics of SP type-O ELISA kits tested
Test-kit
PrioCHECK FMDV
Type O ELISA (P)
Bionote FMD Type-O
Ab ELISA (B)
VDPro FMDV Type-O
Ab b-ELISA (M)
Country/Supplier
Netherlands/
ThermoFisher Scientific
Korea/Bionote
Korea/
Median Diagnostics
ELISA format Blocking ELISA Competitive ELISA Blocking ELISA
Antigen
Inactivated virus
(O1 Manisa, ME-SA)
coated with
trapping mAba
Recombinant VP4231
proteins (O/SKR/JC/2014,
SEA)
coated
Recombinant P13C
proteins (O/SKR/CJ/2000,
ME-SA) coated with
trapping mAb
Cut-off value* PIb≥50% PI≥50% S/Nc≤0.6
a Monoclonal antibody, b Percentage of inhibition, c Sample to negative ratio
*Interpretation of the result : positive (PI≥50%, S/N≤0.6) or negative (PI<50%, S/N>0.6)
Table 3. Sample description
a 50% Protective dose
Group Species
No. of
samples
Vaccine
(No. of samples)
Challenge virus
Vaccinated
Cattle 304 Ma (117), Ab (98), Bc (89) -
Pigs 1236 M (428), A (580), B (228) -
Infected Pigs
601) - O/SKR/AS/2019
932) - O/SKR/BE/2017
Negative3)
Cattle 213 - -
Pigs 155 - -
a Merial, b ARRIAH, c Bago S.A
1) Samples were collected daily from the day of challenge to 19 dpc (days post-contact).
2) Samples were collected daily from the day of challenge to 14 dpc, and after that every week until 162 dpc.
3) Bovine sera from Canada (n=113) and New Zealand (n=100), swine sera from Korea (n=3) and Canada (n=152)
Table 5. Detection rates of antibodies against SP of FMDV type-O in vaccinated animals
Species Group No. of samples
Detection rates of antibodies (%)
P B M VNT*
Cattle
M 117 86.3 100.0 97.4 89.7
A 98 99.0 100.0 99.0 100.0
B 89 95.5 98.9 96.6 97.8
Total : 304 93.1 99.7 97.7 95.4
Pigs
M 428 73.4 81.3 88.1 92.5
A 580 72.8 79.0 88.8 94.0
B 228 99.1 95.6 96.1 99.1
Total : 1236 77.8 82.8 89.9 94.4
The results of all test-kits demonstrated better detection rates of antibodies in sera from cattle vaccinated with
ARRIAH for bovine, whereas sera from pigs vaccinated with Bago resulted in higher detection rates of antibodies.
Also, two domestic kits yielded higher detection rates of antibodies than those of PrioCHECK kit except from pig sera
vaccinated with Bago. When compared to the results of VNT, ELISA kits tended to show lower detection rates of
antibodies than VNT in swine sera, while there was no significant difference between ELISA kits and VNT in bovine
sera.
* NA titer was measured against homologous strain used in vaccination (O Manisa for Merial vaccine, O Primorsky for
ARRIAH vaccine, O1 Campos for Bago vaccine). NA titers ≥16 were interpreted as positive.
Table 4. Diagnostic sensitivity and specificity of three ELISA kits relative to VNT
Species Group
DSea (%) DSpb (%) Kappa value3)
No. of
samples1) P B M
No. of
samples2) P B M P B M
Cattle Vc 290 95.2 100.0 98.3 227 96.9 90.3 93.0 0.918 0.913 0.917
Pigs
V 1167 81.4 83.7 91.3 204 96.6 84.3 81.9 0.547 0.516 0.646
Id 115 80.9 77.4 97.4 193 100.0 99.5 100.0 0.841 0.804 0.979
Total : 1282 81.4 83.2 91.8 242 97.1 86.8 84.7 0.565 0.534 0.687
Although specificities of PrioCHECK kit were higher than those of domestic kits, it was found that domestic kits
tended to show higher sensitivities, except the result of Bionote kit in the group of infected pigs. According to the
results of kappa values, all of three ELISA kits showed at least moderate agreement with VNT regardless of species
and vaccination against FMDV or infection with FMDV.
a Diagnostic sensitivity, b Diagnostic specificity, c Vaccinated, d Infected
1) Only samples showing positive results in VNT (VNT titers≥16) were selected for DSe.
2) Negative sera from unvaccinated and uninfected animals and samples from vaccinated or infected animals giving
negative results in VNT (VNT titers<16) were selected for DSp.
3) Moderate agreement: 0.401~0.600, substantial agreement: 0.601~0.800, almost perfect agreement: 0.801~1.000
DISCUSSION
The results of three ELISAs demonstrated lower positivity rates to SP antibodies
compared to those of VNT against homologous vaccine strains in sera from vaccinated
or infected animals with FMDV type-O. However, the sensitivities of three ELISAs are
supposed to be less affected by the specificity of antigens used in that the results of
kappa values between ELISAs and VNT were identified as moderate or higher level of
agreement. Also, detection rates of two domestic kits tended to be higher than those of
PrioCHECK kit from samples in vaccinated animals, which reflected that various vaccines
in use and field strains from outbreaks in Korea were considered in development of
ELISA kits.
REFERENCES
1. Li Y, et al. Evaluation of the solid phase competition ELISA for detecting antibodies against the
six foot-and-mouth disease virus non-O serotypes. J Virol Methods. 2012 Aug;183(2):125-31.
2. Chénard G, et al. A solid-phase blocking ELISA for detection of type O foot-and-mouth disease
virus antibodies suitable for mass serology. J Virol Methods. 2003 Jan;107(1):89-98.
3. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics.
1977 Mar;33(1):159-74.
Fig. 1. Kinetics of antibody responses to FMDV type-O in sera from pigs infected
with FMDV type-O using three ELISA kits and VNT.
The results were generated from serial samples (1~19 dpc) in pigs infected with FMDV O/SKR/AS/2019 (a), (b) and
from serial samples (1~162 dpc) of pigs infected with FMDV O/SKR/BE/2017 (c), (d). The red dotted line on each
graph indicates cut-off values. PrioCHECK kit and Median kit detected seroconversion as early as 5~7 dpc, which is
equivalent to the results of VNT (4~5 dpc) and Bionote kit detected seroconversion slightly later (7~10 dpc).
a days post-contact
* NA titer was measured against homologous strain used in vaccination. Antibody titers greater than 2.41 (log10256) were
considered as 2.71 (log10512) and antibody titers less than 1.20 (log1016) were considered as 1.00 (log1010).
Table 6. Detection rates of antibodies against SP of FMDV type-O in infected pigs
Challenge virus
No. of
samples
Detection rates of antibodies (%)
P B M VNT*
O/SKR/AS/2019 60 45.0 60.0 73.3 76.7
O/SKR/BE/2017 93 71.0 57.0 73.1 74.2
Total : 153 60.8 58.2 73.2 75.2
Median kit yielded higher detection rates of antibodies than other two kits did and its results were similar to those of
VNT.
* NA titer was measured against homologous strain used in challenge. NA titers ≥16 were interpreted as positive.
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
VNtiter(log10)
dpc (days post-contact)
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
1 2 3 4 5 6 7 8 9 10 14 21 28 49 56 70 162
VNtiter(log10)
dpc (days post-contact)
(a) O/SKR/AS/2019 (ELISA kits) (b) O/SKR/AS/2019 (VNT)
(c) O/SKR/BE/2017 (ELISA kits) (d) O/SKR/BE/2017 (VNT)
0
0.2
0.4
0.6
0.8
1
1.20
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
S/N(Sampletonegativeratio)
PI(Percentageofinhibition,%)
dpc (days post-contact)
P B M
0
0.2
0.4
0.6
0.8
1
1.20
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 14 21 28 49 56 70 162
S/N(Sampletonegativeratio)
PI(Percentageofinhibition,%)
dpc (days post-contact)
P B M

More Related Content

What's hot

OS16 - 2.P1.b FMD Disease Risk Assessment and Progress on Risk-Based Control ...
OS16 - 2.P1.b	FMD Disease Risk Assessment and Progress on Risk-Based Control ...OS16 - 2.P1.b	FMD Disease Risk Assessment and Progress on Risk-Based Control ...
OS16 - 2.P1.b FMD Disease Risk Assessment and Progress on Risk-Based Control ...EuFMD
 
6 disease treatment and control methods 2
6 disease treatment and control methods 26 disease treatment and control methods 2
6 disease treatment and control methods 2Irwan Izzauddin
 
Lecture 10 toxoplasmosis
Lecture 10 toxoplasmosisLecture 10 toxoplasmosis
Lecture 10 toxoplasmosissaid warsame
 
1ملخص لأهم أمراض الدواجن
1ملخص لأهم أمراض الدواجن1ملخص لأهم أمراض الدواجن
1ملخص لأهم أمراض الدواجنDr-Mohamed Saif
 
FOOT AND MOUTH DISEASE ( FMD)
FOOT AND MOUTH DISEASE ( FMD)FOOT AND MOUTH DISEASE ( FMD)
FOOT AND MOUTH DISEASE ( FMD)Shafi'i Abdullahi
 
Foot and mouth disease
Foot and mouth diseaseFoot and mouth disease
Foot and mouth diseaseuzumakiajit
 
Coccivac manual of use
Coccivac manual of use Coccivac manual of use
Coccivac manual of use ibrahim shama
 
African swine fever epidemiology and control in smallholder pig systems: The ...
African swine fever epidemiology and control in smallholder pig systems: The ...African swine fever epidemiology and control in smallholder pig systems: The ...
African swine fever epidemiology and control in smallholder pig systems: The ...ILRI
 
Blue tongue disease in sheep and goats
Blue tongue disease in sheep and goatsBlue tongue disease in sheep and goats
Blue tongue disease in sheep and goatsNirmal Kumar
 
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE ID SCREEN® FMD ...
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE  ID SCREEN® FMD ...PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE  ID SCREEN® FMD ...
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE ID SCREEN® FMD ...EuFMD
 
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...EuFMD
 

What's hot (20)

OS16 - 2.P1.b FMD Disease Risk Assessment and Progress on Risk-Based Control ...
OS16 - 2.P1.b	FMD Disease Risk Assessment and Progress on Risk-Based Control ...OS16 - 2.P1.b	FMD Disease Risk Assessment and Progress on Risk-Based Control ...
OS16 - 2.P1.b FMD Disease Risk Assessment and Progress on Risk-Based Control ...
 
Newcastle disease
Newcastle diseaseNewcastle disease
Newcastle disease
 
6 disease treatment and control methods 2
6 disease treatment and control methods 26 disease treatment and control methods 2
6 disease treatment and control methods 2
 
Viral diseases of aquatic birds. Dr Fares El-Khayat
Viral diseases of aquatic birds. Dr Fares El-KhayatViral diseases of aquatic birds. Dr Fares El-Khayat
Viral diseases of aquatic birds. Dr Fares El-Khayat
 
Aujeszkys disease
Aujeszkys diseaseAujeszkys disease
Aujeszkys disease
 
Babesiosis
BabesiosisBabesiosis
Babesiosis
 
Lecture 10 toxoplasmosis
Lecture 10 toxoplasmosisLecture 10 toxoplasmosis
Lecture 10 toxoplasmosis
 
1ملخص لأهم أمراض الدواجن
1ملخص لأهم أمراض الدواجن1ملخص لأهم أمراض الدواجن
1ملخص لأهم أمراض الدواجن
 
Foot and Mouth Disease
Foot and Mouth DiseaseFoot and Mouth Disease
Foot and Mouth Disease
 
Toxoplasmosis
ToxoplasmosisToxoplasmosis
Toxoplasmosis
 
FOOT AND MOUTH DISEASE ( FMD)
FOOT AND MOUTH DISEASE ( FMD)FOOT AND MOUTH DISEASE ( FMD)
FOOT AND MOUTH DISEASE ( FMD)
 
Foot and mouth disease
Foot and mouth diseaseFoot and mouth disease
Foot and mouth disease
 
Oriental rat flea
Oriental rat fleaOriental rat flea
Oriental rat flea
 
Coccivac manual of use
Coccivac manual of use Coccivac manual of use
Coccivac manual of use
 
African swine fever epidemiology and control in smallholder pig systems: The ...
African swine fever epidemiology and control in smallholder pig systems: The ...African swine fever epidemiology and control in smallholder pig systems: The ...
African swine fever epidemiology and control in smallholder pig systems: The ...
 
HIV & AIDs.pptx
HIV & AIDs.pptxHIV & AIDs.pptx
HIV & AIDs.pptx
 
Blue tongue disease in sheep and goats
Blue tongue disease in sheep and goatsBlue tongue disease in sheep and goats
Blue tongue disease in sheep and goats
 
Norovirus
NorovirusNorovirus
Norovirus
 
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE ID SCREEN® FMD ...
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE  ID SCREEN® FMD ...PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE  ID SCREEN® FMD ...
PROVEN PERFORMANCES FOR FMDV NSP ANTIBODY DETECTION WITH THE ID SCREEN® FMD ...
 
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...
LSD symposium - A. Haegeman - LSDV transmission by stomoxys stable flies less...
 

Similar to COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETECTION OF ANTIBODIES TO FOOT-AND-MOUTH DISEASE VIRUS TYPE-O

VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...
VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...
VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...EuFMD
 
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...EuFMD
 
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...EuFMD
 
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...EuFMD
 
OS16 - 4.P1.d Effect of the Antigen Payload, Polyvalency and Re-Vaccination...
OS16 - 4.P1.d   Effect of the Antigen Payload, Polyvalency and Re-Vaccination...OS16 - 4.P1.d   Effect of the Antigen Payload, Polyvalency and Re-Vaccination...
OS16 - 4.P1.d Effect of the Antigen Payload, Polyvalency and Re-Vaccination...EuFMD
 
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...EuFMD
 
Apvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonApvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonMerial EMEA
 
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...EuFMD
 
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Rafael Monleon
 
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...EuFMD
 
Development and comparison of capture enzyme linked immunosorbent assay and i...
Development and comparison of capture enzyme linked immunosorbent assay and i...Development and comparison of capture enzyme linked immunosorbent assay and i...
Development and comparison of capture enzyme linked immunosorbent assay and i...Alexander Decker
 
Prospects for preventing bacterial meningitis Prospects for preventing bact...
Prospects for preventing bacterial meningitis 	 Prospects for preventing bact...Prospects for preventing bacterial meningitis 	 Prospects for preventing bact...
Prospects for preventing bacterial meningitis Prospects for preventing bact...MedicineAndHealthUSA
 
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...EuFMD
 
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...Dr. Md. Ehsanul Haque
 
Poster benito SIDiLV BVD/BDV
Poster benito SIDiLV BVD/BDVPoster benito SIDiLV BVD/BDV
Poster benito SIDiLV BVD/BDVSergio Exopol
 
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIA
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIAPoster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIA
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIAFAO
 
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Álvaro L. Valiñas
 
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Álvaro L. Valiñas
 

Similar to COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETECTION OF ANTIBODIES TO FOOT-AND-MOUTH DISEASE VIRUS TYPE-O (20)

VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...
VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...
VALIDATION OF RECOMBINANT PROTEIN-BASED ELISA FOR DETECTION OF ANTIBODIES TO ...
 
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
 
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...
OS20 - Comparison of diagnostic performances of three commercial ELISA kits f...
 
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...
EXPERIMENTAL EVALUATION OF FOOT-AND-MOUTH DISEASE O SKR VACCINE: PROTECTIVE E...
 
OS16 - 4.P1.d Effect of the Antigen Payload, Polyvalency and Re-Vaccination...
OS16 - 4.P1.d   Effect of the Antigen Payload, Polyvalency and Re-Vaccination...OS16 - 4.P1.d   Effect of the Antigen Payload, Polyvalency and Re-Vaccination...
OS16 - 4.P1.d Effect of the Antigen Payload, Polyvalency and Re-Vaccination...
 
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...
DURATION OF IMMUNITY IN CATTLE AND PIGS UNDER NATIONAL VACCINATION PROGRAMME ...
 
Apvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonApvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparison
 
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
 
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
 
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...
A new pan FMDV DAS antigen ELISA prototype using multi-serotype-reactive mono...
 
Development and comparison of capture enzyme linked immunosorbent assay and i...
Development and comparison of capture enzyme linked immunosorbent assay and i...Development and comparison of capture enzyme linked immunosorbent assay and i...
Development and comparison of capture enzyme linked immunosorbent assay and i...
 
Prospects for preventing bacterial meningitis Prospects for preventing bact...
Prospects for preventing bacterial meningitis 	 Prospects for preventing bact...Prospects for preventing bacterial meningitis 	 Prospects for preventing bact...
Prospects for preventing bacterial meningitis Prospects for preventing bact...
 
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...
A PAN-SEROTYPE SOLID PHASE BLOCKING ELISA PROTOTYPE FOR DETECTION OF STRUCTUR...
 
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...
Sensitivity and Specificity of an In-house Sandwich ELISA Kit for Newcastle D...
 
Poster benito SIDiLV BVD/BDV
Poster benito SIDiLV BVD/BDVPoster benito SIDiLV BVD/BDV
Poster benito SIDiLV BVD/BDV
 
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIA
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIAPoster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIA
Poster: READY-TO-USE KITS FOR DETECTION OF ANTIBODY TO FMDV SEROTYPES O, A, ASIA
 
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
 
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
Variation analysis of Swine influenza virus (SIV) H1N1 sequences in experimen...
 
Elisa hi ai quail
Elisa hi ai quailElisa hi ai quail
Elisa hi ai quail
 
JVM_116_2_norovirus
JVM_116_2_norovirusJVM_116_2_norovirus
JVM_116_2_norovirus
 

More from EuFMD

VADEMOS VAccine Demand Estimation Model for FMD.pdf
VADEMOS VAccine Demand Estimation Model for FMD.pdfVADEMOS VAccine Demand Estimation Model for FMD.pdf
VADEMOS VAccine Demand Estimation Model for FMD.pdfEuFMD
 
Vaccine delivery and demand workshop
Vaccine delivery and demand workshopVaccine delivery and demand workshop
Vaccine delivery and demand workshopEuFMD
 
Emergency vaccination workshop presentations 30 May 2023.pdf
Emergency vaccination workshop presentations 30 May 2023.pdfEmergency vaccination workshop presentations 30 May 2023.pdf
Emergency vaccination workshop presentations 30 May 2023.pdfEuFMD
 
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...EuFMD
 
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...EuFMD
 
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...EuFMD
 
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...EuFMD
 
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...EuFMD
 
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...EuFMD
 
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...EuFMD
 
LSD symposium - L. Pite - Combating lumpy skin disease in Albania
LSD symposium - L. Pite - Combating lumpy skin disease in AlbaniaLSD symposium - L. Pite - Combating lumpy skin disease in Albania
LSD symposium - L. Pite - Combating lumpy skin disease in AlbaniaEuFMD
 
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...EuFMD
 
LSD symposium - J. Chan - Lumpy skin disease in Hong Kong
LSD symposium - J. Chan - Lumpy skin disease in Hong KongLSD symposium - J. Chan - Lumpy skin disease in Hong Kong
LSD symposium - J. Chan - Lumpy skin disease in Hong KongEuFMD
 
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...EuFMD
 
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...EuFMD
 
LSD symposium - P. Malik - Lumpy skin disease experience from India
LSD symposium - P. Malik - Lumpy skin disease experience from IndiaLSD symposium - P. Malik - Lumpy skin disease experience from India
LSD symposium - P. Malik - Lumpy skin disease experience from IndiaEuFMD
 
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...LSD symposium - G. Cattoli - Lessons from ten years of experience building me...
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...EuFMD
 
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...EuFMD
 
LSD symposium - E. Klemen - Modes of transmission of lumpy skin disease
LSD symposium - E. Klemen - Modes of transmission of lumpy skin diseaseLSD symposium - E. Klemen - Modes of transmission of lumpy skin disease
LSD symposium - E. Klemen - Modes of transmission of lumpy skin diseaseEuFMD
 
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...EuFMD
 

More from EuFMD (20)

VADEMOS VAccine Demand Estimation Model for FMD.pdf
VADEMOS VAccine Demand Estimation Model for FMD.pdfVADEMOS VAccine Demand Estimation Model for FMD.pdf
VADEMOS VAccine Demand Estimation Model for FMD.pdf
 
Vaccine delivery and demand workshop
Vaccine delivery and demand workshopVaccine delivery and demand workshop
Vaccine delivery and demand workshop
 
Emergency vaccination workshop presentations 30 May 2023.pdf
Emergency vaccination workshop presentations 30 May 2023.pdfEmergency vaccination workshop presentations 30 May 2023.pdf
Emergency vaccination workshop presentations 30 May 2023.pdf
 
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...
LSD symposium - N. Galon - Thinking out of the pox lessons and thoughts on LS...
 
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...
LSD symposium - C. E. Lamien - Molecular epidemiological investigation of LSD...
 
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...
LSD symposium - I. Gluecks - Cattle farming in Kenya, Africa livestock health...
 
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...
LSD symposium - G. Pezzoni - Development of a pen-side test for the detection...
 
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...
LSD symposium - W. Philips - Evaluation of the efficacy of live attenuated he...
 
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...
LSD symposium - A. Sprygin - Subclinical infection its role in transmission a...
 
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...
LSD symposium - Z. Fatima- Investigation of suspected outbreaks of lumpy skin...
 
LSD symposium - L. Pite - Combating lumpy skin disease in Albania
LSD symposium - L. Pite - Combating lumpy skin disease in AlbaniaLSD symposium - L. Pite - Combating lumpy skin disease in Albania
LSD symposium - L. Pite - Combating lumpy skin disease in Albania
 
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...
LSD symposium - E. Tuppurainen - Update on global distribution of lumpy skin ...
 
LSD symposium - J. Chan - Lumpy skin disease in Hong Kong
LSD symposium - J. Chan - Lumpy skin disease in Hong KongLSD symposium - J. Chan - Lumpy skin disease in Hong Kong
LSD symposium - J. Chan - Lumpy skin disease in Hong Kong
 
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...
LSD symposium - N. Zainuddin - Indonesian experience on simultaneous LSD and ...
 
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...
LSD symposium - R. Ainsworth - Lumpy skin disease (LSD) in Southeast Asia Mar...
 
LSD symposium - P. Malik - Lumpy skin disease experience from India
LSD symposium - P. Malik - Lumpy skin disease experience from IndiaLSD symposium - P. Malik - Lumpy skin disease experience from India
LSD symposium - P. Malik - Lumpy skin disease experience from India
 
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...LSD symposium - G. Cattoli - Lessons from ten years of experience building me...
LSD symposium - G. Cattoli - Lessons from ten years of experience building me...
 
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...
LSD symposium - H. Bergmann - Systemic review and expert ranking of potential...
 
LSD symposium - E. Klemen - Modes of transmission of lumpy skin disease
LSD symposium - E. Klemen - Modes of transmission of lumpy skin diseaseLSD symposium - E. Klemen - Modes of transmission of lumpy skin disease
LSD symposium - E. Klemen - Modes of transmission of lumpy skin disease
 
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...
LSD symposium - A. Van Schalkwyk - Evolutionary changes between LSDV strains ...
 

Recently uploaded

Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentabdeli bhadarva
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Catherine Liao
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramLevi Shapiro
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxBright Chipili
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxRohit chaurpagar
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghanahealthwatchghana
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Dr. Aryan (Anish Dhakal)
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsShweta
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...Catherine Liao
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Catherine Liao
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxDr KHALID B.M
 
Fundamental of Radiobiology -SABBU.pptx
Fundamental of Radiobiology  -SABBU.pptxFundamental of Radiobiology  -SABBU.pptx
Fundamental of Radiobiology -SABBU.pptxSabbu Khatoon
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesTina Purnat
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdfKs doctor
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...kevinkariuki227
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxgauripg8
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 

Recently uploaded (20)

Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
Fundamental of Radiobiology -SABBU.pptx
Fundamental of Radiobiology  -SABBU.pptxFundamental of Radiobiology  -SABBU.pptx
Fundamental of Radiobiology -SABBU.pptx
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 

COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETECTION OF ANTIBODIES TO FOOT-AND-MOUTH DISEASE VIRUS TYPE-O

  • 1. 1 EuFMD | Open Session special edition | #OS20se Comparison of Diagnostic Performances of Three Commercial ELISA Kits for Detection of Antibodies to Foot-and-Mouth Disease Virus Type-O Doheon Kwon, YouJin Han, JiHyun Lee, Hyun Mi Pyo, Eun-Jin Choi, Wonseok Shin, JaeMyoung Kim and Mi-Young Park Foot and Mouth Disease Diagnostic Division, Animal and Plant Quarantine Agency, 177, Hyeoksin 8-ro, Gimcheon-si, Gyeongsangbuk-do, Republic of Korea INTRODUCTION Vaccination has been the main strategy to prevent and control Foot-and-mouth Disease (FMD) in Korea since 2010 and three FMD vaccines containing various strains has been routinely used under national vaccination program since 2019. Furthermore, three commercial ELISA kits have been licensed for detection of antibodies against structural proteins (SP) of FMDV (Foot-and-mouth Disease Virus) to estimate vaccine-induced immunity. These include PrioCHECK SP Type-O ELISA, accredited internationally and two domestic solid-phase ELISA kits coated with recombinant protein-based antigens, the latter two of which were approved in 2020. Since these various factors were involved, variability in serological test results owing to differences in the antigenic specificity of tests according to the particular virus strains and antibody reagents utilized in the tests may affect the reliability of serological results. Therefore, we investigated diagnostic performances of three ELISAs used for sero-surveillance to monitor vaccine coverage and assess herd immunity in cattle and pigs. MATERIALS & METHODS A total of three FMDV SP type O ELISA kits licensed in Korea (Table 1) were evaluated using 1540 sera collected from pigs and cattle vaccinated with one of three FMD vaccines as described below (Table 2). In addition, 153 sera from unvaccinated pigs experimentally infected with FMDV O/SKR/BE/2017 or O/SKR/AS/2019 and 368 negative sera from unvaccinated and uninfected animals were tested too. Also, neutralizing antibody (NA) titers were determined with virus neutralization tests (VNT) against homologous virus strains. RESULTS Country Supplier Serotype Antigens PD50 a UK Merial Animal Health Ltd. O+A O Manisa, O 3039, A22 Iraq ≥3PD50 Russia FGBI ARRIAH O+A O Primorsky, A Zabaikalsky ≥6PD50 Argentina Biogenesis Bago S.A O+A O1 Campos, A24 Cruzeiro, A2001 Argentina ≥6PD50 Table 2. Summary of FMD vaccines approved for routine use in Korea Table 1. Characteristics of SP type-O ELISA kits tested Test-kit PrioCHECK FMDV Type O ELISA (P) Bionote FMD Type-O Ab ELISA (B) VDPro FMDV Type-O Ab b-ELISA (M) Country/Supplier Netherlands/ ThermoFisher Scientific Korea/Bionote Korea/ Median Diagnostics ELISA format Blocking ELISA Competitive ELISA Blocking ELISA Antigen Inactivated virus (O1 Manisa, ME-SA) coated with trapping mAba Recombinant VP4231 proteins (O/SKR/JC/2014, SEA) coated Recombinant P13C proteins (O/SKR/CJ/2000, ME-SA) coated with trapping mAb Cut-off value* PIb≥50% PI≥50% S/Nc≤0.6 a Monoclonal antibody, b Percentage of inhibition, c Sample to negative ratio *Interpretation of the result : positive (PI≥50%, S/N≤0.6) or negative (PI<50%, S/N>0.6) Table 3. Sample description a 50% Protective dose Group Species No. of samples Vaccine (No. of samples) Challenge virus Vaccinated Cattle 304 Ma (117), Ab (98), Bc (89) - Pigs 1236 M (428), A (580), B (228) - Infected Pigs 601) - O/SKR/AS/2019 932) - O/SKR/BE/2017 Negative3) Cattle 213 - - Pigs 155 - - a Merial, b ARRIAH, c Bago S.A 1) Samples were collected daily from the day of challenge to 19 dpc (days post-contact). 2) Samples were collected daily from the day of challenge to 14 dpc, and after that every week until 162 dpc. 3) Bovine sera from Canada (n=113) and New Zealand (n=100), swine sera from Korea (n=3) and Canada (n=152) Table 5. Detection rates of antibodies against SP of FMDV type-O in vaccinated animals Species Group No. of samples Detection rates of antibodies (%) P B M VNT* Cattle M 117 86.3 100.0 97.4 89.7 A 98 99.0 100.0 99.0 100.0 B 89 95.5 98.9 96.6 97.8 Total : 304 93.1 99.7 97.7 95.4 Pigs M 428 73.4 81.3 88.1 92.5 A 580 72.8 79.0 88.8 94.0 B 228 99.1 95.6 96.1 99.1 Total : 1236 77.8 82.8 89.9 94.4 The results of all test-kits demonstrated better detection rates of antibodies in sera from cattle vaccinated with ARRIAH for bovine, whereas sera from pigs vaccinated with Bago resulted in higher detection rates of antibodies. Also, two domestic kits yielded higher detection rates of antibodies than those of PrioCHECK kit except from pig sera vaccinated with Bago. When compared to the results of VNT, ELISA kits tended to show lower detection rates of antibodies than VNT in swine sera, while there was no significant difference between ELISA kits and VNT in bovine sera. * NA titer was measured against homologous strain used in vaccination (O Manisa for Merial vaccine, O Primorsky for ARRIAH vaccine, O1 Campos for Bago vaccine). NA titers ≥16 were interpreted as positive. Table 4. Diagnostic sensitivity and specificity of three ELISA kits relative to VNT Species Group DSea (%) DSpb (%) Kappa value3) No. of samples1) P B M No. of samples2) P B M P B M Cattle Vc 290 95.2 100.0 98.3 227 96.9 90.3 93.0 0.918 0.913 0.917 Pigs V 1167 81.4 83.7 91.3 204 96.6 84.3 81.9 0.547 0.516 0.646 Id 115 80.9 77.4 97.4 193 100.0 99.5 100.0 0.841 0.804 0.979 Total : 1282 81.4 83.2 91.8 242 97.1 86.8 84.7 0.565 0.534 0.687 Although specificities of PrioCHECK kit were higher than those of domestic kits, it was found that domestic kits tended to show higher sensitivities, except the result of Bionote kit in the group of infected pigs. According to the results of kappa values, all of three ELISA kits showed at least moderate agreement with VNT regardless of species and vaccination against FMDV or infection with FMDV. a Diagnostic sensitivity, b Diagnostic specificity, c Vaccinated, d Infected 1) Only samples showing positive results in VNT (VNT titers≥16) were selected for DSe. 2) Negative sera from unvaccinated and uninfected animals and samples from vaccinated or infected animals giving negative results in VNT (VNT titers<16) were selected for DSp. 3) Moderate agreement: 0.401~0.600, substantial agreement: 0.601~0.800, almost perfect agreement: 0.801~1.000 DISCUSSION The results of three ELISAs demonstrated lower positivity rates to SP antibodies compared to those of VNT against homologous vaccine strains in sera from vaccinated or infected animals with FMDV type-O. However, the sensitivities of three ELISAs are supposed to be less affected by the specificity of antigens used in that the results of kappa values between ELISAs and VNT were identified as moderate or higher level of agreement. Also, detection rates of two domestic kits tended to be higher than those of PrioCHECK kit from samples in vaccinated animals, which reflected that various vaccines in use and field strains from outbreaks in Korea were considered in development of ELISA kits. REFERENCES 1. Li Y, et al. Evaluation of the solid phase competition ELISA for detecting antibodies against the six foot-and-mouth disease virus non-O serotypes. J Virol Methods. 2012 Aug;183(2):125-31. 2. Chénard G, et al. A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology. J Virol Methods. 2003 Jan;107(1):89-98. 3. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159-74. Fig. 1. Kinetics of antibody responses to FMDV type-O in sera from pigs infected with FMDV type-O using three ELISA kits and VNT. The results were generated from serial samples (1~19 dpc) in pigs infected with FMDV O/SKR/AS/2019 (a), (b) and from serial samples (1~162 dpc) of pigs infected with FMDV O/SKR/BE/2017 (c), (d). The red dotted line on each graph indicates cut-off values. PrioCHECK kit and Median kit detected seroconversion as early as 5~7 dpc, which is equivalent to the results of VNT (4~5 dpc) and Bionote kit detected seroconversion slightly later (7~10 dpc). a days post-contact * NA titer was measured against homologous strain used in vaccination. Antibody titers greater than 2.41 (log10256) were considered as 2.71 (log10512) and antibody titers less than 1.20 (log1016) were considered as 1.00 (log1010). Table 6. Detection rates of antibodies against SP of FMDV type-O in infected pigs Challenge virus No. of samples Detection rates of antibodies (%) P B M VNT* O/SKR/AS/2019 60 45.0 60.0 73.3 76.7 O/SKR/BE/2017 93 71.0 57.0 73.1 74.2 Total : 153 60.8 58.2 73.2 75.2 Median kit yielded higher detection rates of antibodies than other two kits did and its results were similar to those of VNT. * NA titer was measured against homologous strain used in challenge. NA titers ≥16 were interpreted as positive. 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 VNtiter(log10) dpc (days post-contact) 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 1 2 3 4 5 6 7 8 9 10 14 21 28 49 56 70 162 VNtiter(log10) dpc (days post-contact) (a) O/SKR/AS/2019 (ELISA kits) (b) O/SKR/AS/2019 (VNT) (c) O/SKR/BE/2017 (ELISA kits) (d) O/SKR/BE/2017 (VNT) 0 0.2 0.4 0.6 0.8 1 1.20 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 S/N(Sampletonegativeratio) PI(Percentageofinhibition,%) dpc (days post-contact) P B M 0 0.2 0.4 0.6 0.8 1 1.20 10 20 30 40 50 60 70 80 90 100 1 2 3 4 5 6 7 8 9 10 14 21 28 49 56 70 162 S/N(Sampletonegativeratio) PI(Percentageofinhibition,%) dpc (days post-contact) P B M